Research

Publications

Master
Heading

Selected Publication Supported by ACE-3M

Heading

2022

Content

1) Villanueva H, Wells GA, Miller MT, Villanueva M, Pathak R, Castro P, Ittmann MM, Sikora AG, Lerner SP. Characterizing treatment resistance in muscle invasive bladder cancer using the chicken egg chorioallantoic membrane patient-derived xenograft model. Heliyon. Volume 8, Issue 12, 2022. e12570. ISSN 2405-8440, https://doi.org/10.1016/j.heliyon.2022.e12570.

2) Chattopadhyay C, Bhattacharya R, Roszik J, Khan FS, Wells GA, Villanueva H, Qin Y, Bhattacharya R, Patel SP, Grimm EA. Targeting IRS-1/2 in Uveal Melanoma Inhibits In Vitro Cell Growth, Survival and Migration, and In Vivo Tumor Growth. Cancers (Basel). 2022 Dec 19;14(24). doi: 10.3390/cancers14246247. PubMed PMID: 36551732; PubMed Central PMCID: PMC9777326.

3) Souto EP, Dobrolecki LE, Villanueva H, Sikora AG, Lewis MT. In Vivo Modeling of Human Breast Cancer Using Cell Line and Patient-Derived Xenografts. J Mammary Gland Biol Neoplasia. 2022 Jun;27(2):211-230. doi: 10.1007/s10911-022-09520-y. Epub 2022 Jun 13. Erratum in: J Mammary Gland Biol Neoplasia. 2022 Jul 26;: PMID: 35697909; PMCID: PMC9433358.

4) Vyas A, Gomez-Casal R, Cruz-Rangel S, Villanueva H, Sikora AG, Rajagopalan P, Basu D, Pacheco J, Hammond GRV, Kiselyov K, Duvvuri U. Lysosomal inhibition sensitizes TMEM16A-expressing cancer cells to chemotherapy. Proc Natl Acad Sci U S A. 2022 Mar 22;119(12):e2100670119. doi: 10.1073/pnas.2100670119. Epub 2022 Mar 14. PMID: 35286200; PMCID: PMC8944912.

Heading

2021

Content

CHAF1A Blocks Neuronal Differentiation and Promotes Neuroblastoma Oncogenesis via Metabolic Reprogramming. 
Tao L, Moreno-Smith M, Ibarra-García-Padilla R, Milazzo G, Drolet NA, Hernandez BE, Oh YS, Patel I, Kim JJ, Zorman B, Patel T, Kamal AHM, Zhao Y, Hicks J, Vasudevan SA, Putluri N, Coarfa C, Sumazin P, Perini G, Parchem RJ, Uribe RA, Barbieri E. Adv Sci (Weinh). 2021 Oct;8(19):e2005047. doi: 10.1002/advs.202005047. Epub 2021 Aug 8. PMID: 34365742 

Restoration of the molecular clock is tumor suppressive in neuroblastoma. 
Moreno-Smith M, Milazzo G, Tao L, Fekry B, Zhu B, Mohammad MA, Di Giacomo S, Borkar R, Reddy KRK, Capasso M, Vasudevan SA, Sumazin P, Hicks J, Putluri N, Perini G, Eckel-Mahan K, Burris TP, Barbieri E. Nat Commun. 2021 Jun 28;12(1):4006. doi: 10.1038/s41467-021-24196-4. PMID: 34183658

The synergy of BET inhibitors with aurora A kinase inhibitors in MYCN-amplified neuroblastoma is heightened with functional TP53. 
Yi JS, Sias-Garcia O, Nasholm N, Hu X, Iniguez AB, Hall MD, Davis M, Guha R, Moreno-Smith M, Barbieri E, Duong K, Koach J, Qi J, Bradner JE, Stegmaier K, Weiss WA, Gustafson WC. Neoplasia. 2021 Jun;23(6):624-633. doi: 10.1016/j.neo.2021.05.003. Epub 2021 Jun 7. PMID: 34107377 

p53 loss activates prometastatic secretory vesicle biogenesis in the Golgi. 
Tan X, Banerjee P, Shi L, Xiao GY, Rodriguez BL, Grzeskowiak CL, Liu X, Yu J, Gibbons DL, Russell WK, Creighton CJ, Kurie JM. Sci Adv. 2021 Jun 18;7(25):eabf4885. doi: 10.1126/sciadv.abf4885. Print 2021 Jun. PMID: 34144984

A protumorigenic secretory pathway activated by p53 deficiency in lung adenocarcinoma. 
Tan X, Shi L, Banerjee P, Liu X, Guo HF, Yu J, Bota-Rabassedas N, Rodriguez BL, Gibbons DL, Russell WK, Creighton CJ, Kurie JM. J Clin Invest. 2021 Jan 4;131(1):e137186. doi: 10.1172/JCI137186. PMID: 32931483

RON signaling promotes therapeutic resistance in ESR1 mutant breast cancer. 
Dustin D, Gu G, Beyer AR, Herzog SK, Edwards DG, Lin H, Gonzalez TL, Grimm SL, Coarfa C, Chan DW, Kim BJ, De La O JP, Ellis MJ, Liu D, Li S, Welm AL, Fuqua SAW. Br J Cancer. 2021 Jan;124(1):191-206. doi: 10.1038/s41416-020-01174-z. Epub 2020 Dec 1. PMID: 33257837

Hormonal modulation of ESR1 mutant metastasis. 
Gu G, Tian L, Herzog SK, Rechoum Y, Gelsomino L, Gao M, Du L, Kim JA, Dustin D, Lo HC, Beyer AR, Edwards DG, Gonzalez T, Tsimelzon A, Huang HJ, Fernandez NM, Grimm SL, Hilsenbeck SG, Liu D, Xu J, Alaniz A, Li S, Mills GB, Janku F, Kittler R, Zhang XH, Coarfa C, Foulds CE, Symmans WF, Andò S, Fuqua SAW. Oncogene. 2021 Feb;40(5):997-1011. doi: 10.1038/s41388-020-01563-x. Epub 2020 Dec 15. PMID: 33323970

Heading

2020

Content

Neurofibromin Is an Estrogen Receptor-α Transcriptional Co-repressor in Breast Cancer. 
Zheng ZY, Anurag M, Lei JT, Cao J, Singh P, Peng J, Kennedy H, Nguyen NC, Chen Y, Lavere P, Li J, Du XH, Cakar B, Song W, Kim BJ, Shi J, Seker S, Chan DW, Zhao GQ, Chen X, Banks KC, Lanman RB, Shafaee MN, Zhang XH, Vasaikar S, Zhang B, Hilsenbeck SG, Li W, Foulds CE, Ellis MJ, Chang EC. Cancer Cell. 2020 Mar 16;37(3):387-402.e7. doi: 10.1016/j.ccell.2020.02.003. Epub 2020 Mar 5. PMID: 32142667 

Repurposing type I-F CRISPR-Cas system as a transcriptional activation tool in human cells. 
Chen Y, Liu J, Zhi S, Zheng Q, Ma W, Huang J, Liu Y, Liu D, Liang P, Songyang Z. Nat Commun. 2020 Jun 19;11(1):3136. doi: 10.1038/s41467-020-16880-8. PMID: 32561716 

Heading

2019

Content

A novel disorder involving dyshematopoiesis, inflammation, and HLH due to aberrant CDC42 function. 
Lam MT, Coppola S, Krumbach OHF, Prencipe G, Insalaco A, Cifaldi C, Brigida I, Zara E, Scala S, Di Cesare S, Martinelli S, Di Rocco M, Pascarella A, Niceta M, Pantaleoni F, Ciolfi A, Netter P, Carisey AF, Diehl M, Akbarzadeh M, Conti F, Merli P, Pastore A, Levi Mortera S, Camerini S, Farina L, Buchholzer M, Pannone L, Cao TN, Coban-Akdemir ZH, Jhangiani SN, Muzny DM, Gibbs RA, Basso-Ricci L, Chiriaco M, Dvorsky R, Putignani L, Carsetti R, Janning P, Stray-Pedersen A, Erichsen HC, Horne A, Bryceson YT, Torralba-Raga L, Ramme K, Rosti V, Bracaglia C, Messia V, Palma P, Finocchi A, Locatelli F, Chinn IK, Lupski JR, Mace EM, Cancrini C, Aiuti A, Ahmadian MR, Orange JS, De Benedetti F, Tartaglia M. J Exp Med. 2019 Dec 2;216(12):2778-2799. doi: 10.1084/jem.20190147. Epub 2019 Oct 10. PMID: 31601675 

Genome-wide profiling of adenine base editor specificity by EndoV-seq. 
Liang P, Xie X, Zhi S, Sun H, Zhang X, Chen Y, Chen Y, Xiong Y, Ma W, Liu D, Huang J, Songyang Z. Nat Commun. 2019 Jan 8;10(1):67. doi: 10.1038/s41467-018-07988-z. PMID: 30622278 

A kinome-wide RNAi screen identifies ERK2 as a druggable regulator of Shank3 stability. 
Wang L, Adamski CJ, Bondar VV, Craigen E, Collette JR, Pang K, Han K, Jain A, Y Jung S, Liu Z, Sifers RN, Holder JL Jr, Zoghbi HY. Mol Psychiatry. 2020 Oct;25(10):2504-2516. doi: 10.1038/s41380-018-0325-9. Epub 2019 Jan 29. PMID: 30696942